TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02942147

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional or Pulse Radiofrequency
Description: In the radiofrequency method applied to Group 1 and Group 3 patients, the targeted facet joints were marked while the fluoroscope was in antero-posterior position. During this marking, the fluoroscope was directed towards cephal or caudal so that at whatever level the median ramus block was to be involved the endplate of that vertebra would become a straight line. The connection point of the superior articular protrusion was marked on the fluoroscope using the transverse process and the intervention was applied with a 22G, 10-cm radiofrequency cannula with 0.5 cm active tip in a way that bone contact was established through the tunneled vision technique. The intervention was completed after the radiofrequency procedure was applied at four levels.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional or Pulse Radiofrequency
Description: In the radiofrequency method applied to Group 1 and Group 3 patients, the targeted facet joints were marked while the fluoroscope was in antero-posterior position. During this marking, the fluoroscope was directed towards cephal or caudal so that at whatever level the median ramus block was to be involved the endplate of that vertebra would become a straight line. The connection point of the superior articular protrusion was marked on the fluoroscope using the transverse process and the intervention was applied with a 22G, 10-cm radiofrequency cannula with 0.5 cm active tip in a way that bone contact was established through the tunneled vision technique. The intervention was completed after the radiofrequency procedure was applied at four levels.
Study: NCT02235753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic interval training, long interval
Description: The intensity of HIT-L sessions (cycle ergometer) will be increased during 3 to 6 months from 60% of VO2peak to 90% which will be the target intensity from 6 to 12 months. The protocol includes four 3 min exercise bouts with a 4 min recovery (pedaling at 0 W) between bouts. Exercise session will last ca. 40 min, with 12 min of HIT, warm-up and recovery. The intensity of the 3 min exercise bouts will be based on VO2peak at baseline and after 6 months. Meanwhile, the estimated VO2peak from the submaximal test will be used to adjust the training intensity in HIT sessions. Training will be conducted in a group of 1-3 HIT-L patients with ECG monitoring and supervised by physician.
Study: NCT02232516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: romidepsin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01468727

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: xylitol wipe
Description: Parents were instructed to wipe their infants' teeth and gums three times per day with two wipes each time after feeding in addition to their daily tooth brushing.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo wipe
Description: Parents were instructed to wipe their infants' teeth and gums three times per day with two wipes each time after feeding in addition to their daily tooth brushing.
Study: NCT02313935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LLM
Description: LLM training Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FFA
Description: PTC training Participants use the FitForAll exergaming computer platform as the physical training component (PTC)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain Fitness
Description: CTC training Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VideoGrade
Description: Active cognitive training by use of the VideoGrade software by AUTH.
Study: NCT01565629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer assisted cognitive behavioral therapy.
Description: Those who choose to participate will be required to attend 4 assessments - pre-treatment (week 0), mid-treatment (week 8), post-treatment, and a 4th assessment for a 3 month Follow-up. All children regardless of condition will follow the CCBT protocol (Camp Cope-A-lot), which is the computer-assisted intervention being examined in this study. The first 6 levels of this program are skill building levels to be completed by the user. The remaining 6 levels are completed with the therapist and consist of exposure tasks and rehearsal geared toward each child.
Study: NCT03511261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10% Curcumin mucoadhesive gel
Description: Group 1 10%of mucoadhesive gel for topical application two times per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin capsules 500mg
Description: Group 2 curcumin 500 mg capsules for oral intake two times per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% curcumin mucoadhesive gel + Curcumin capsules 250 mg
Description: Group 3 5% curcumin mucoadhesive gel topical application two times per day + curcumin 250 mg capsules for oral intake two times per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Group 4 placebo capsules for oral intake two times per day
Study: NCT03042013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8273
Description: Oral
Study: NCT04474145

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PT group
Description: The physiotherapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise (stretching, ROM exercise, and strengthening), three times a week, and will be continued for 8 weeks or until total recovery of the symptoms. The stretching exercise program is similar to the stretching exercise described above. For mimicking injection in the Comb group, patients in the PT group will receive 2cc 1% xylocain injection at the posterior deltoid muscle.
Study: NCT00427154

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosiglitazone
Description: Tablets, 4 mg once or twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhaled human insulin
Description: Treat-to-target dose titration scheme, inhalation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Tablets, 2000 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Tablets, 2000 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: Tablets, 8 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: Tablets, 8 mg/day.
Study: NCT02305407

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Revascularization
Description: Most patients in this group will be performed combined procedures of superficial temporal to middle cerebral artery bypass (STA-MCA) and encephalo-duro-myo-synangiosis (EDMS). Patients not suitable for combined procedures will be performed EDMS.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Description: Patients will be medically treated with antiplatelets, antiepileptics, antihypertensives and vasodilators depending on the presentation.
Study: NCT04077125

Intervention type: DRUG
Intervention: Rifaximin
Description: to investigate changes in cerebral, splanchnic hemodynamics and endothelial function in cirrhotic patients with MHE after 15 days of rifaximin therapy (1200 mg/d)
Study: NCT01228552

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical, intra-oral ketoprofen gel
Description: Ketoprofen gel will be applied, using a cotton applicator, to the gingival mucosa at the onset of migraine. A second application may be used at 20 minutes, if necessary.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Placebo gel will be applied, using a cotton applicator, to the gingival mucosa at the onset of migraine. A second application may be used at 20 minutes, if necessary.
Study: NCT00486434

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SMC021 Oral Calcitonin
Description: 0.8mg SMC021 (Oral Calcitoinin) twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SMC021 Placebo
Description: Placebo orally, twice daily
Study: NCT01724762

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing Orientation
Description: * Control group: patients who did not read the informative manual concerning bed bath and received only the unit's routine information~* Intervention group: patients who received nursing orientation and read the informative manual concerning bed bath
Study: NCT04416854

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: resection of primary tumor
Description: resection of primary lesion with unresectablely metastatic colon cancer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX
Description: Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6
Description: Oxaliplatin 85mg/m2, leucovorin 400mg/m2 ivgtt d1 and 5-FU 400 mg/m2 IV bolus d1，2400 mg/m2 CIV 46h, d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: Oxaliplatin 85mg/m2, leucovorin 400mg/m2 ivgtt d1 and 5-FU 400 mg/m2 IV bolus d1，2400 mg/m2 CIV 46h, d1
Study: NCT02940652

Intervention type: RADIATION
Intervention: Magnetic resonance imaging
Description: No intervention - description of the position of the LMA obtained during routine elective MRI scanning of the brain and/or cervical spine
Study: NCT04470739

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: chest x-ray
Description: First Chest X-ray in the first 6 hours of infants
Study: NCT04381741

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-7×19 CAR-T plus PD1 monoclonal antibody
Description: Three different doses of CD19-7×19 CAR-T (1×106/kg、2×106/kg、3×106/kg) plus 200mg Tislelizumab every 3 weeks for 6 times
Study: NCT03545334

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visionsense™ VS3 - Stereoscopic High Definition Visualisation System (VS3-3DHD)
Description: Injection of ICG intradermally around the scar of the primary excision of the tumour and transcutaneous assessment of fluorescence with the VS3-3DHD camera (Visionsense™ VS3 - Stereoscopic High Definition Visualisation System ).
Study: NCT03292263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: iv infusion 70-100 mg/m2 on day -3, -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: iv infusion 100 mg on day -3, +17

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplantation
Description: peripheral blood stem cell transfusion at day 0
Study: NCT03703206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ultrasound guided injection of local anesthetic between the popliteal artery and the capsule of the knee (iPACK)
Description: nerve block for posterior knee pain after a TKA.
Study: NCT01186861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: Tablet administered with food and with up to 200 mL of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Tablet administered at least 2 hours after food with up to 200 mL of water

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: erlotinib
Description: Tablet administered at least 2 hours after food with up to 200 mL of water
Study: NCT03318289

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ving Tsun
Description: The VT training regimen is designed to improve reactive balance control, lower extremity muscle strength and balance confidence in the elderly. It comprises 9 VT sticking-hand drills that must be practised with a partner. Participants will be trained to respond rapidly to upper body perturbations and to maintain body balance. Those joined the VT training group will attend a one-hour supervised VT training session at an elderly community centre 2 times per week for 12 weeks.
Study: NCT01186861

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Tablet administered at least 2 hours after food with up to 200 mL of water
Study: NCT02944799

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Discontinuation of alendronate treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: Daily dietary supplement of 800mg calcium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium
Description: Daily dietary supplement of 800mg calcium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Daily dietary supplement of 38 micrograms vitamin D

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: Daily dietary supplement of 38 micrograms vitamin D
Study: NCT04527172

Intervention type: DIAGNOSTIC_TEST
Intervention: neuromuscular ultrasound
Description: ultrasound to visualize the peripheral nerves of lupus patients and to compare it with results of the raditional electrophysiological studies

Intervention type: DIAGNOSTIC_TEST
Intervention: neuromuscular ultrasound
Description: ultrasound to visualize the peripheral nerves of lupus patients and to compare it with results of the raditional electrophysiological studies
Study: NCT01293396

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: Patients received insulin aspart before breakfast and before lunch.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart 30
Description: Patients received biphasic insulin aspart 30 before breakfast and before lunch.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart 70
Description: Patients received biphasic insulin aspart 70 before breakfast and before lunch.
Study: NCT04207567

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bodyweight exercises (push-ups, angled-rows, bodyweight squats) on weekdays
Description: Participants will be instructed to perform one set each of push-ups, angled-rows, and bodyweight squats every weekday. They will be given the equipment and training necessary to properly perform the exercises. They will also be trained in the Tiny Habits® Method and receive digital coaching.
Study: NCT02639117

Intervention type: DRUG
Group type: OTHER
Intervention: Vismodegib
Description: Vismodegib 150 mgs po qd for 3 months
Study: NCT00390780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: miconazole Lauriad
Description: 50 mg buccal tablet once a day for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clotrimazole
Description: 10mg troches administered Five Times a Day for 14 days
Study: NCT03179098

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modified Weeks protocol
Description: The modified Weeks group (GWM) will apply the protocol suggested by Flowers (2002), the positioning will be maintained and at rest will be done electromyographic registers, active goniometry and EVA. Soon afterwards the patients will be submitted to the whirlwind for 20 minutes at a temperature of 41 ° C performing active flexion and elbow extension movements. After the swirl the patients will be submitted to a stretching maintained for 10 minutes with load proportional to the force captured during MVIC according to the pain of the patient. The load will be positioned through a leather device 20 cm from the lateral epicondyle of the elbow.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CIVM
Description: Patients underwent electromyographic analysis for the determination of maximal voluntary isometric contraction. The force will be collected for 5 seconds during a CIVM, in which a load cell model MM50 (Kratos, Cotia, SP, Brazil) will be positioned between the floor and the forearm of the volunteer, being coupled to a leather device at 20 cm Make the lateral epicondyle of the elbow. The angle between the forearm and the cable containing a load cell with a 90 degree service.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CIVM
Description: Patients underwent electromyographic analysis for the determination of maximal voluntary isometric contraction. The force will be collected for 5 seconds during a CIVM, in which a load cell model MM50 (Kratos, Cotia, SP, Brazil) will be positioned between the floor and the forearm of the volunteer, being coupled to a leather device at 20 cm Make the lateral epicondyle of the elbow. The angle between the forearm and the cable containing a load cell with a 90 degree service.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GC- Sustained Stretching
Description: The control group will be applied to sustained stretching, patients will be placed in the supine position with abduction of the shoulder of 30 ° in the plane of the scapula and the forearm in neutral throughout the entire test and the elbow will be supported in a towel to avoid discomfort And compression in the region of the olecranon.
Study: NCT02003742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-1207
Description: Single TRUS-guided intraprostatic injection of 2.5 mg of NX-1207

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: 1 film coated, prolonged release tablet of tamsulosin 0.4 mg, to be taken orally (p.o.) QD
Study: NCT00620620

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled placebo
Description: Inhaled Staccato Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Zaleplon 0.5 mg
Description: Inhaled Staccato Zaleplon 0.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Zaleplon 1 mg
Description: Inhaled Staccato Zaleplon 1 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Zaleplon 2 mg
Description: Inhaled Staccato Zaleplon 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Zaleplon 4 mg
Description: Inhaled Staccato Zaleplon 4 mg
Study: NCT01454401

Intervention type: DEVICE
Group type: OTHER
Intervention: LeucoPatch treatment
Description: weekly
Study: NCT00278265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX followed by fludarabine
Description: MTX should be administered with 10-20mg weekly, calculated according to the body weight. Fludarabine should be administered with 25mg/m2 on day 1-3 of 28 days, up to 4 cycles
Study: NCT01101386

Intervention type: DRUG
Intervention: Voriconazole
Description: Patients will be started on voriconazole 6 mg/kg IV q12h on day 1, then 4 mg/kg IV q12h thereafter.
Study: NCT00396630

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Rotarix
Description: Two-dose oral vaccination.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: Two-dose oral vaccination.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two-dose oral administration.
Study: NCT04551183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgeons CT scan analysis
Description: Surgeons extract diameter by hand (Gold Standard method) then realised a semi-manual segmentation of the images to extract volumes and diameters of the aorta (espacially AAA)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRAEVAorta CT scan analysis
Description: CT scans are analysed by the software under investigation : PRAEVAorta. It will extract volumes and diameters of the aorta (AAA espacially)
Study: NCT04049097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arimoclomol
Description: 2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily during breakfast, early afternoon, and at bedtime
Study: NCT03474393

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: systematic intensive therapy
Description: intensive telephone och internet Contact with diabetes nurse for coaching and guidance over 4 months and 4 Control visits
Study: NCT03727763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: 960mg po bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 500mg/m2 iv gtt (14 days per course)
Study: NCT03313895

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic & Cognitive Training (ACT)
Description: ACT stands for combined aerobic exercise and cognitive training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cycling Only
Description: Cycling on a recumbent stationary cycle

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training Only
Description: Engage in cognitive training on a computer

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Stretching and Mental Stimulating Activities
Description: Stretching exercises and mental stimulating activities on a computer
Study: NCT01881763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine 1-2 mgr/ kg IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methohexital
Description: Methohexital 0.5-1mg/kg IV
Study: NCT04404569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXQ-350
Description: BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 is administered by intravenous (IV) infusion in 28-day cycles